Cerebrolysin in 67 first-degree relatives of people with Alzheimer’s disease
Observational study · 2018
- What was studied
- 67 first-degree relatives, 27 with objectively confirmed cognitive difficulty and 40 without.
- Main finding
- Clinicians rated 77.6% improved after the course. Both baseline subgroups received Cerebrolysin.
Clinician-rated improvement · 77.6% of 67 · After the one-month course
Reported findings and study design
Before-and-after study, stratified by baseline cognitive difficulty.
Population or model 67 first-degree relatives, 27 with objectively confirmed cognitive difficulty and 40 without.
Dose, route and schedule
Cerebrolysin 20 mL intravenously in 100 mL saline per treatment day for a one-month course.
Protocol source ↗ · Original indexed abstract, treatment cohort and outcome summary.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Clinician-rated improvement | 77.6% of 67 | After the one-month course |
| MMSE and MoCA | Both subgroups improved significantly versus baseline | The abstract gives no arm-level score changes. |
Source for these results ↗ · Reviewed 2026-11-15
Study limitations and source details
Study limitations
- The abstract describes no untreated group. The measurements were short term. Overlap with other reports from the same center is unresolved.
Related publications may describe some of the same participants or experiments.
Source details
Original indexed abstract, treatment cohort and outcome summary.
Sources checked
Citation
N. D. Selezneva, I. F. Roshchina, G. I. Korovaitseva, S. I. Gavrilova. Cerebrolysin in 67 first-degree relatives of people with Alzheimer’s disease Korsakov Journal of Neurology and Psychiatry. 2018;118(10):30–36.
Study source ↗ · DOI 10.17116/jnevro201811810130 · Bibliography entry · Link to this summary